These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 16290163)

  • 21. Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.
    Pena A; Murat B; Trueba M; Ventura MA; Wo NC; Szeto HH; Cheng LL; Stoev S; Guillon G; Manning M
    J Med Chem; 2007 Feb; 50(4):835-47. PubMed ID: 17300166
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of YM218, a nonpeptide vasopressin V(1A) receptor-selective antagonist, on rat mesangial cell hyperplasia and hypertrophy.
    Tahara A; Tsukada J; Tomura Y; Suzuki T; Yatsu T; Shibasaki M
    Vascul Pharmacol; 2007 Jun; 46(6):463-9. PubMed ID: 17395547
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Binding and signal transduction characteristics of the nonpeptide vasopressin V1A receptor-selective antagonist YM218 in cultured rat mesangial cells.
    Tahara A; Tsukada J; Tomura Y; Kusayama T; Momose K; Taniguchi N; Suzuki T; Yatsu T; Shibasaki M
    Pharmacology; 2006; 78(2):81-90. PubMed ID: 16966841
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimization of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine-5-ylidene)acetamide derivatives as arginine vasopressin V2 receptor agonists and discussion of their binding modes.
    Tsukamoto I; Koshio H; Orita M; Saitoh C; Yanai-Inamura H; Kitada-Nozawa C; Yamamoto E; Yatsu T; Sakamoto S; Tsukamoto S
    Bioorg Med Chem; 2009 Dec; 17(24):8161-7. PubMed ID: 19900813
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis and structure-activity investigation of novel vasopressin hypotensive peptide agonists.
    Manning M; Stoev S; Cheng LL; Wo NC; Chan WY
    J Pept Sci; 1999 Nov; 5(11):472-90. PubMed ID: 10587312
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Highly potent and orally active non-peptide arginine vasopressin antagonists for both V1A and V2 receptors: synthesis and pharmacological properties of 4'-[(4,4-difluoro-5-methylidene-2,3,4,5-tetrahydro-1H-1-benzoazepin-1-y l)carbonyl]-2-phenylbenzanilide derivatives.
    Shimada Y; Taniguchi N; Matsuhisa A; Sakamoto K; Yatsu T; Tanaka A
    Chem Pharm Bull (Tokyo); 2000 Nov; 48(11):1644-51. PubMed ID: 11086891
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design of oxytocin antagonists, which are more selective than atosiban.
    Manning M; Stoev S; Cheng LL; Wo NC; Chan WY
    J Pept Sci; 2001 Sep; 7(9):449-65. PubMed ID: 11587184
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An investigation of position 3 in arginine vasopressin with aliphatic, aromatic, conformationally-restricted, polar and charged amino acids.
    Stoev S; Cheng LL; Olma A; Klis WA; Manning M; Sawyer WH; Wo NC; Chan WY
    J Pept Sci; 1999 Mar; 5(3):141-53. PubMed ID: 10323558
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and structure-activity relationships of 5,6,7,8-tetrahydro-4H-thieno[3,2-b]azepine derivatives: novel arginine vasopressin antagonists.
    Cho H; Murakami K; Nakanishi H; Fujisawa A; Isoshima H; Niwa M; Hayakawa K; Hase Y; Uchida I; Watanabe H; Wakitani K; Aisaka K
    J Med Chem; 2004 Jan; 47(1):101-9. PubMed ID: 14695824
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preparation of non-peptide, highly potent and selective antagonists of arginine vasopressin V1A receptor by introduction of alkoxy groups.
    Shimada Y; Taniguchi N; Matsuhisa A; Yatsu T; Tahara A; Tanaka A
    Chem Pharm Bull (Tokyo); 2003 Sep; 51(9):1075-80. PubMed ID: 12951451
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design, Synthesis, and Biological Evaluation of 3-Benzazepin-1-ols as NR2B-Selective NMDA Receptor Antagonists.
    Tewes B; Frehland B; Schepmann D; Schmidtke KU; Winckler T; Wünsch B
    ChemMedChem; 2010 May; 5(5):687-95. PubMed ID: 20340125
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular modelling of the vasopressin V2 receptor/antagonist interactions.
    Czaplewski C; Kaźmierkiewicz R; Ciarkowski J
    Acta Biochim Pol; 1998; 45(1):19-26. PubMed ID: 9701492
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel strategies for the design of receptor-selective vasopressin analogues: Aib-substitution and retro-inverso transformation.
    Howl J; Prochazka Z; Wheatley M; Slaninová J
    Br J Pharmacol; 1999 Oct; 128(3):647-52. PubMed ID: 10516644
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vasopressin promotes cardiomyocyte hypertrophy via the vasopressin V1A receptor in neonatal mice.
    Hiroyama M; Wang S; Aoyagi T; Oikawa R; Sanbe A; Takeo S; Tanoue A
    Eur J Pharmacol; 2007 Mar; 559(2-3):89-97. PubMed ID: 17275806
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis and evaluation of nonpeptide substituted spirobenzazepines as potent vasopressin antagonists.
    Xiang MA; Chen RH; Demarest KT; Gunnet J; Look R; Hageman W; Murray WV; Combs DW; Rybczynski PJ; Patel M
    Bioorg Med Chem Lett; 2004 Jun; 14(12):3143-6. PubMed ID: 15149662
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pyridobenzodiazepines: a novel class of orally active, vasopressin V2 receptor selective agonists.
    Failli AA; Shumsky JS; Steffan RJ; Caggiano TJ; Williams DK; Trybulski EJ; Ning X; Lock Y; Tanikella T; Hartmann D; Chan PS; Park CH
    Bioorg Med Chem Lett; 2006 Feb; 16(4):954-9. PubMed ID: 16297621
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis and structure-activity relationships of a series of benzazepine derivatives as 5-HT2C receptor agonists.
    Shimada I; Maeno K; Kondoh Y; Kaku H; Sugasawa K; Kimura Y; Hatanaka K; Naitou Y; Wanibuchi F; Sakamoto S; Tsukamoto S
    Bioorg Med Chem; 2008 Mar; 16(6):3309-20. PubMed ID: 18083579
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacological characterization of RWJ-676070, a dual vasopressin V(1A)/V(2) receptor antagonist.
    Gunnet JW; Wines P; Xiang M; Rybczynski P; Andrade-Gordon P; de Garavilla L; Parry TJ; Cheung WM; Minor L; Demarest KT; Maryanoff BE; Damiano BP
    Eur J Pharmacol; 2008 Aug; 590(1-3):333-42. PubMed ID: 18599033
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Conformational aspects of differences in requirements for oxytocin and vasopressin receptors.
    Oldziej S; Ciarkowski J; Liwo A; Shenderovich MD; Grzonka Z
    J Recept Signal Transduct Res; 1995; 15(1-4):703-13. PubMed ID: 8903974
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Position 4 analogues of [deamino-Cys(1)] arginine vasopressin exhibit striking species differences for human and rat V(2)/V(1b) receptor selectivity.
    Guillon G; Pena A; Murat B; Derick S; Trueba M; Ventura MA; Szeto HH; Wo N; Stoev S; Cheng LL; Manning M
    J Pept Sci; 2006 Mar; 12(3):190-8. PubMed ID: 16130178
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.